1-6 of 6
Selina M. Luger
Close
Sort by
Journal Articles

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Clinical Trials & Observations
Jessica K. Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary-Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch, Liat Flaishon, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7494–7500.
https://doi.org/10.1182/bloodadvances.2023010943
Published: 2023
Journal Articles

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Clinical Trials & Observations
Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger
Journal: Blood Advances
Blood Adv (2023) 7 (2): 196–204.
https://doi.org/10.1182/bloodadvances.2022007791
Published: 2023
Includes: Supplemental data
Journal Articles

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Clinical Trials & Observations
Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Harry P. Erba, Frederick R. Appelbaum, Richard A. Larson, Theresa H.M. Keegan, Wendy Stock
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4085–4092.
https://doi.org/10.1182/bloodadvances.2022007197
Published: 2022
Includes: Supplemental data
Journal Articles

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Andrew H. Matthews, Alexander E. Perl, Selina M. Luger, Alison W. Loren, Saar I. Gill, David L. Porter, Daria V. Babushok, Ivan P. Maillard, Martin P. Carroll, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Vikram R. Paralkar, Ximena Jordan Bruno, Wei-Ting Hwang, David Margolis, Keith W. Pratz
Journal: Blood Advances
Blood Adv (2022) 6 (13): 3997–4005.
https://doi.org/10.1182/bloodadvances.2022007265
Published: 2022
Includes: Supplemental data
Journal Articles

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Clinical Trials & Observations
Chezi Ganzel, Ju-Whei Lee, Hugo F. Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M. Lazarus, Larry D. Cripe, Dan Douer, Peter H. Wiernik, Jacob M. Rowe, Martin S. Tallman, Mark R. Litzow
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4560–4568.
https://doi.org/10.1182/bloodadvances.2021004999
Published: 2021
Journal Articles

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Clinical Trials & Observations
Anjali S. Advani, Eric Larsen, Kristina Laumann, Selina M. Luger, Michaela Liedtke, Meenakshi Devidas, Zhiguo Chen, Jun Yin, Matthew C. Foster, David Claxton, Kristin Coffan, Martin S. Tallman, Frederick R. Appelbaum, Harry Erba, Richard M. Stone, Stephen P. Hunger, Jennifer L. McNeer, Mignon L. Loh, Elizabeth Raetz, Naomi Winick, William Carroll, Richard A. Larson, Wendy Stock
Journal: Blood Advances
Blood Adv (2021) 5 (2): 504–512.
https://doi.org/10.1182/bloodadvances.2020002439
Published: 2021
Includes: Supplemental data